atai Life Sciences backed by positive sector readthrough from Compass Phase 3 data, analysts say

Jefferies maintains a 'Buy' rating on atai Life Sciences (ATAI) with a $6 price target, citing positive readthrough from Compass Pathways' (CMPS) successful Phase 3 trial for COMP360 in treatment-resistant depression (TRD), which broadly validates the psychedelics sector. While atai holds a 7% stake in Compass, analysts are primarily focused on atai's BPL-003, an intranasal 5-MeO-DMT currently in a 196-patient Phase 2b study for TRD. Jefferies anticipates a significant 50-100% stock appreciation for atai in H2 2025 following the BPL-003 Phase 2b readout and potential merger with Beckley Psytech, especially if it demonstrates strong efficacy and fits the established in-clinic treatment paradigm of J&J's Spravato, a multi-billion dollar market.

Analysis

Jefferies maintains its 'Buy' rating on atai Life Sciences, citing a positive sector-wide readthrough from Compass Pathways' successful Phase 3 trial of COMP360 in treatment-resistant depression (TRD). While atai's 7% stake in Compass provides some benefit, the key implication is the broader validation of psychedelics for treating major CNS disorders, which enhances investor confidence. The primary focus for atai is its own asset, BPL-003, an intranasal 5-MeO-DMT formulation currently in a 196-patient Phase 2b study for TRD. A positive outcome from this trial is expected to trigger a merger with Beckley Psytech, giving atai full ownership of the asset and potentially driving a 50% to 100% stock appreciation in the second half of 2025. Analysts have set a high efficacy bar for BPL-003, suggesting a meaningful stock move requires a 5-point separation on the MADRS depression scale at week four, which would surpass the 3.6-point reduction reported by Compass for COMP360. Furthermore, atai's strategy to fit BPL-003 within the established two-hour, in-clinic treatment model of Johnson & Johnson's Spravato, a drug with a $1.3 billion-plus run rate, significantly de-risks the commercial pathway and addresses a proven market.

Key Decisions for Investors

• Investors should view the upcoming Phase 2b data for BPL-003 in H2 2025 as the primary near-term catalyst for atai, with analysts forecasting a potential 50-100% re-rating upon success.
• Monitor the BPL-003 trial results for a key efficacy metric: a mean reduction on the MADRS scale of at least 5 points over placebo, as this is the analyst-specified threshold for a significant market reaction.
• Consider the strategic value of atai's commercial plan to align BPL-003 with the proven in-clinic model of Spravato, which substantially mitigates go-to-market risk compared to novel treatment paradigms.
• Given the high-impact nature of the upcoming data and Jefferies' $6 price target implying 142% upside, accumulating a position may be warranted, while remaining aware of the binary risk inherent in clinical trial outcomes.